- Home
- ACRS vs CFBK Comparison
ACRS vs CFBK Comparison
Compare ACRS & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CFBK
- Stock Information
- Founded
- ACRS 2012
- CFBK 1892
- Country
- ACRS United States
- CFBK United States
- Employees
- ACRS N/A
- CFBK N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CFBK Major Banks
- Sector
- ACRS Health Care
- CFBK Finance
- Exchange
- ACRS Nasdaq
- CFBK Nasdaq
- Market Cap
- ACRS 165.7M
- CFBK 159.5M
- IPO Year
- ACRS 2015
- CFBK 1998
- Fundamental
- Price
- ACRS $1.95
- CFBK $25.10
- Analyst Decision
- ACRS Strong Buy
- CFBK Buy
- Analyst Count
- ACRS 9
- CFBK 1
- Target Price
- ACRS $9.25
- CFBK $29.00
- AVG Volume (30 Days)
- ACRS 891.2K
- CFBK 33.3K
- Earning Date
- ACRS 11-05-2025
- CFBK 10-29-2025
- Dividend Yield
- ACRS N/A
- CFBK 1.27%
- EPS Growth
- ACRS N/A
- CFBK 36.66
- EPS
- ACRS N/A
- CFBK 2.77
- Revenue
- ACRS $16,789,000.00
- CFBK $52,793,000.00
- Revenue This Year
- ACRS N/A
- CFBK $39.98
- Revenue Next Year
- ACRS N/A
- CFBK $10.47
- P/E Ratio
- ACRS N/A
- CFBK $9.06
- Revenue Growth
- ACRS N/A
- CFBK 20.91
- 52 Week Low
- ACRS $1.05
- CFBK $19.23
- 52 Week High
- ACRS $5.17
- CFBK $31.17
- Technical
- Relative Strength Index (RSI)
- ACRS 56.76
- CFBK 60.21
- Support Level
- ACRS $2.01
- CFBK $24.80
- Resistance Level
- ACRS $2.16
- CFBK $25.97
- Average True Range (ATR)
- ACRS 0.10
- CFBK 0.45
- MACD
- ACRS -0.01
- CFBK 0.04
- Stochastic Oscillator
- ACRS 47.44
- CFBK 48.52
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.